• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Harmony Biosciences Holdings Inc (NQ: HRMY )

    35.83 +0.92 (+2.64%)
    Streaming Delayed Price Updated: 1:58 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 212,392
    Open 35.10
    Bid (Size) 35.78 (7)
    Ask (Size) 35.85 (7)
    Prev. Close 34.91
    Today's Range 34.88 - 35.83
    52wk Range 22.89 - 41.61
    Shares Outstanding 57,031,297
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
    Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. 
    Via Benzinga
    Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
    HRMY earnings call for the period ending September 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial

    Performance

    YTD
    +16.37%
    +16.37%
    1 Month
    +3.11%
    +3.11%
    3 Month
    +5.41%
    +5.41%
    6 Month
    +14.55%
    +14.55%
    1 Year
    +49.73%
    +49.73%

    More News

    Read More
    Analyst Expectations For Harmony Biosciences's Future
    Via Benzinga
    Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
    Via Investor's Business Daily
    Earnings Outlook For Harmony Biosciences
    Via Benzinga
    Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
    Via Benzinga
    Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
    Via Benzinga
    Unveiling 6 Analyst Insights On Harmony Biosciences
    Via Benzinga
    Analyst Expectations For Harmony Biosciences's Future
    Via Benzinga
    A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
    Via Benzinga
    Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
    From Harmony Biosciences
    Via GlobeNewswire
    7 Cheap Biotech Stocks With Major Upside Potential
    Via InvestorPlace
    7 Undervalued Biotech Stocks to Buy for Big-Time Returns
    Via InvestorPlace
    Key Takeaways From Harmony Biosciences Analyst Ratings
    Via Benzinga
    Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
    Via Benzinga
    7 Biotech Stocks to Buy on the Dip: June 2024
    Via InvestorPlace
    Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
    Via Benzinga
    Topics Earnings
    Exposures Financial
    Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
    From Harmony Biosciences
    Via GlobeNewswire
    Updates: HRMY, MELI, SWAV
    Via Talk Markets
    Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.